By Adam Bonislawski

Investment firm Nxt2b has signed an agreement to purchase 49 percent of all outstanding shares of Olink Bioscience for an undisclosed amount.

According to Olle Kämpe, a scientific advisor at Nxt2b and a professor of molecular medicine at Uppsala University, the firm sees great potential in packaging Olink's proximity ligation technology in ready-to-use formats for scientific, pharmaceutical, and clinical researchers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.